Nearly one in three U.S. adults now lives with a diagnosed seasonal allergy, eczema, or food allergy, according to 2024 data from the CDC’s National Center for Health Statistics. Despite how common allergic disease is, treatment has changed very little for most patients: an antihistamine in the morning, a nasal spray at night, and a repeat trip to the pharmacy every allergy season. Sublingual immunotherapy has offered an alternative to that cycle for years, but access to it has been limited by geography and the demands of a clinic-based treatment schedule. A newly published study is showing what happens when that model moves entirely to telehealth.
Inside the Study
Published in Frontiers in Allergy in 2026, the retrospective cohort study led by Chet Tharpe and colleagues analyzed real-world outcomes from patients receiving personalized sublingual immunotherapy through Curex, a telemedicine allergy platform. Every patient underwent remote allergen sensitization testing before receiving a formulation built around their specific triggers, then reported symptoms, medication use, and any adverse events through structured surveys over time.
What stands out is the setting. Most sublingual immunotherapy research comes out of controlled clinical environments with limited enrollment. This dataset was pulled from a platform with tens of thousands of registered patients, giving researchers a real-world view of how sublingual drops perform outside a lab, administered by people managing their own treatment at home.
What the Data Showed
The safety findings were reassuring. Adverse events were infrequent, and the ones that did occur were overwhelmingly mild, things like localized itching or throat irritation rather than serious systemic reactions. Higher-grade events were rare. That pattern lines up with the broader body of sublingual immunotherapy research and adds weight to the argument that allergen immunotherapy can be delivered safely outside a traditional allergist’s office when patients are properly screened and monitored remotely.
Why It Matters Beyond Allergy Care
This study is a useful case study for telehealth more broadly. Chronic condition management has been shifting toward remote-first models across specialties, from dermatology to metabolic health, and allergy care has been slower to make that transition given the perception that immunotherapy requires in-person supervision. Real-world evidence at this scale challenges that assumption directly.
For an industry still building trust in remote-first specialty care, published, peer-reviewed data carries more weight than marketing claims ever could. As more telehealth providers publish outcomes at scale, sublingual drops may end up being one of the clearest examples of a chronic treatment that works just as well delivered to a patient’s door as it does inside a clinic.